Milting Hendrik, Scholz Christian, Arusoglu Latif, Freitag Meike, Cebulla Ramona, Jaquet Kornelia, Körfer Reiner, V Lewinski Dirk, Kassner Astrid, Brodde Otto-Erich, Kögler Harald, El Banayosy Aly, Pieske Burkert
Ruhr-Universität Bochum; Herz- and Diabeteszentrum NRW, Erich and Hanna Klessmann-Institut für Kardiovaskuläre Forschung and Entwicklung; 32545 Bad Oeynhausen, Germany.
J Mol Cell Cardiol. 2006 Sep;41(3):441-50. doi: 10.1016/j.yjmcc.2006.04.010. Epub 2006 Jun 12.
In terminal failing hearts, adrenergic receptors are downregulated and intracellular adrenergic signal transduction is inhibited. Mechanical circulatory support by ventricular assist devices (VAD) is used to bridge patients to heart transplantation. Mechanical unloading by VAD may induce reverse remodeling in heart transplantation (HTx) candidates. However, little is known on beta-adrenergic receptor subtype regulation and adrenergic signal transduction under VAD-support. We investigated paired myocardial samples from 16 VAD-supported patients and 9 non-failing donor hearts. We analyzed beta-adrenergic receptor subtype regulation by real-time PCR and radioligand binding and cardiac troponin I phosphorylation (by phospho-cTnI-specific antibodies). We found that the beta1-adrenergic receptor (beta1AR) is downregulated at VAD-implantation on mRNA and protein levels whereas the beta2-adrenergic receptor (beta2AR) was not. After VAD-support, beta1AR protein but not its mRNA was upregulated, whereas the degree of cTnI-phosphorylation was reduced. Upregulation of beta1AR was enhanced by beta blocking medication during VAD-support. However, in 9 out of 15 patients, beta1AR-density remained below the 0.25 percentile of donor hearts. VAD-support is associated with partial normalization of the betaAR-signal transduction pathways. This beneficial effect is related to a posttranscriptional increase in beta1AR-density.
在终末期衰竭心脏中,肾上腺素能受体下调,细胞内肾上腺素能信号转导受到抑制。心室辅助装置(VAD)提供的机械循环支持用于帮助患者过渡到心脏移植。VAD的机械卸载可能会在心脏移植(HTx)候选者中诱导逆向重构。然而,关于VAD支持下β-肾上腺素能受体亚型调节和肾上腺素能信号转导的了解甚少。我们研究了16例接受VAD支持的患者和9个非衰竭供体心脏的配对心肌样本。我们通过实时PCR、放射性配体结合分析β-肾上腺素能受体亚型调节以及心肌肌钙蛋白I磷酸化(使用磷酸化cTnI特异性抗体)。我们发现,在植入VAD时,β1-肾上腺素能受体(β1AR)在mRNA和蛋白质水平均下调,而β2-肾上腺素能受体(β2AR)则未下调。在VAD支持后,β1AR蛋白上调但其mRNA未上调,而cTnI磷酸化程度降低。在VAD支持期间,β受体阻滞剂药物增强了β1AR的上调。然而,在15例患者中的9例中,β1AR密度仍低于供体心脏的第0.25百分位数。VAD支持与βAR信号转导通路的部分正常化有关。这种有益作用与β1AR密度的转录后增加有关。